intensity of post treatment surveillance and survival in
play

INTENSITY OF POST-TREATMENT SURVEILLANCE AND SURVIVAL IN COLORECTAL - PowerPoint PPT Presentation

INTENSITY OF POST-TREATMENT SURVEILLANCE AND SURVIVAL IN COLORECTAL CANCER PATIENTS George J. Chang, MD, MS, FACS, FASCRS Professor of Surgical Oncology & of Health Services Research The University of Texas, MD Anderson Cancer Center


  1. INTENSITY OF POST-TREATMENT SURVEILLANCE AND SURVIVAL IN COLORECTAL CANCER PATIENTS George J. Chang, MD, MS, FACS, FASCRS Professor of Surgical Oncology & of Health Services Research The University of Texas, MD Anderson Cancer Center Co-Chair, Cancer Care Delivery Research Program Alliance for Clinical Trials in Oncology Network

  2. COI Disclosures George J. Chang, MD, MS, FACS, FASCRS  Consultancy – Johnson and Johnson; MORE Health

  3. 1.8 million Colorectal Cancer Survivors in US

  4. Goals of Surveillance Management of Detection of long-term sequelae Recurrence of treatment Post-treatment Continuity of Care Pyschosocial well- being

  5. Surveillance Guidelines Vary Widely CT scan every 6 months CEA every 3 months 5 years CT scan twice in 3 years CEA every 6 months 3 years No further testing

  6. N=735 A Curative surgery No curative surgery

  7. Scanxiety (n) “scan zi et ee”: Anxiety and worry that accompanies the period of time before undergoing or receiving the results of a medical examination (such as MRI or CT scan).

  8. Does Higher Surveillance Intensity Improve Detection of Recurrence or Survival?

  9. Cohort Selection - 1  Collaboration to improve process for recurrence ascertainment within the NCDB  Random sampling of 10 colorectal cancer patients within each facility for primary data abstraction

  10. Cohort Selection - 2 14,784 Biopsy Records 61,075 CEA Records 40,272 Imaging Records 16,967 Endoscopy Records

  11. Facility Predict each patient Test use among Compare clustering effect facility # of survivors w/o effectiveness of for O/E tests/pt for all demographic recurrence intensity by survivors P<0.0001 imaging (n=6279) facility (n=8529) tumor P<0.0001 CEA

  12. Intensity and Recurrence Detection Mean LI:1.6 (95%CI 1.6-1.7) HI: 2.9 (95%CI 2.8-2.9) IMAGING INTENSITY CEA INTENSITY

  13. Intensity and Overall Survival Mean LI:1.6 (95%CI 1.6-1.7) HI: 2.9 (95%CI 2.8-2.9) Overall survival by imaging test intensity Overall survival by CEA test intensity (log rank test for OE<1 vs OE≥1p=0.9118) (log rank test for OE<1 vs OE≥1 p=0.1849) 100 100 95.98 95.79 90.32 90.13 95.35 95.16 90 90 84.43 84.15 89.39 89.22 Overall survival (%) Overall survival (%) 78.70 78.38 83.39 80 80 83.13 74.27 73.62 77.77 77.48 73.70 70 70 73.09 OE<1 OE<1 60 60 OE≥1 OE≥1 50 50 0 1 2 3 4 5 0 1 2 3 4 5 Years after surveillance start date Years after surveillance start date

  14. Intensity & Salvage Surgical Treatment Mean LI:1.6 (95%CI 1.6-1.7) HI: 2.9 (95%CI 2.8-2.9) CEA INTENSITY IMAGING INTENSITY 10 10 8 8 p=0.27, O/E<1 vs O/E>=1 for stage III p=0.27, O/E<1 vs O/E>=1 for stage III Resection rate (%) Resection rate (%) 6 6 p=0.41, O/E<1 vs O/E>1 for stage II p=0.41, O/E<1 vs O/E>1 for stage II 4 4 p=0.68, O/E<1 vs O/E>=1 for stage I p=0.68, O/E<1 vs O/E>=1 for stage I 2 2 0 0 0 1 2 3 4 5 0 1 2 3 4 5 Years after surveillance start date Years after surveillance start date Stage I, O/E<1 Stage II, O/E<1 Stage III, O/E<1 Stage I, O/E<1 Stage II, O/E<1 Stage III, O/E<1 Stage I, O/E>=1 Stage II, O/E>=1 Stage III, O/E>=1 Stage I, O/E>=1 Stage II, O/E>=1 Stage III, O/E>=1

  15. Summary  Intensification of surveillance has a negligible impact on the detection of recurrence or survival  May slightly increase rate surgery for distant recurrence  No need to image more frequently than once/year  Earlier - stage patients may require less follow-up  Follow-up care should emphasize  Management of treatment associated toxicity  Health promotion and secondary prevention  Psychosocial well-being https://crcdecisiontool.mdanderson.org

  16. Thank You gchang@mdanderson.org @coloncancerdoc

Download Presentation
Download Policy: The content available on the website is offered to you 'AS IS' for your personal information and use only. It cannot be commercialized, licensed, or distributed on other websites without prior consent from the author. To download a presentation, simply click this link. If you encounter any difficulties during the download process, it's possible that the publisher has removed the file from their server.

Recommend


More recommend